专利检索 ap:("Rigel Pharmaceuticals, Inc.") AND inv:"Sambaiah Thota" 第 1 页

1.

发明授权
Compositions and methods for inhibition of the JAK pathway 有权

公开(公告)号：US09732073B2

公开(公告)日：2017-08-15

申请号：US14974143

申请日：2015-12-18

申请人： Rigel Pharmaceuticals, Inc.

发明人： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong

IPC分类号： C07D403/04 , A61K31/506 , C07D413/12 , C07D239/42 , C07D239/48 , C07D401/12 , C07D403/12 , C07D413/14 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/395 , C07D498/04 , C07F7/10 , A61K45/06 , C07D401/14 , C07D417/12 , C07F7/08 , C07D285/22

CPC分类号： C07D413/12 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/3955 , A61K45/06 , C07D239/42 , C07D239/48 , C07D285/22 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D413/14 , C07D417/12 , C07D498/04 , C07F7/0812 , C07F7/10

摘要： The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

2.

发明申请
COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY 审中-公开

公开(公告)号：US20170121291A1

公开(公告)日：2017-05-04

申请号：US15290918

申请日：2016-10-11

申请人： Rigel Pharmaceuticals, Inc.

发明人： Ankush Argade , Arvinder Sran , David Carroll , Jeffrey Clough , Kin Tso , Somasekhar Bhamidipati , Sambaiah Thota , Rajinder Singh , Vanessa Taylor , Hui Li , Esteban Masuda

IPC分类号： C07D239/48 , C07D403/12 , C07D417/12 , C07D401/14 , C07D498/04 , C07D413/14 , C07D405/12 , C07D401/12 , C07D413/12

CPC分类号： C07D239/48 , A61K31/505 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D498/04

摘要： The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

3.

发明授权
Carboxamide, sulfonamide and amine compounds and methods for using the same 有权
标题翻译：甲酰胺，磺酰胺和胺化合物及其使用方法

公开(公告)号：US08895578B2

公开(公告)日：2014-11-25

申请号：US14053328

申请日：2013-10-14

申请人： Rigel Pharmaceuticals, Inc.

发明人： Ihab S. Darwish , Jiaxin Yu , Hui Hong , Rajinder Singh , Sambaiah Thota , Xiang Xu

IPC分类号： A61K31/454 , A61K31/437 , C07D471/04 , C07D401/06 , C07D401/14 , C07D401/12

CPC分类号： C07D471/04 , C07D401/06 , C07D401/12 , C07D401/14

摘要： Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R4, D, E, J, T, p, q and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

摘要翻译： 公开了羧酰胺，磺酰胺和胺化合物，以及药物组合物和使用方法。一个实施方案是具有其中R 1，R 2，R 4，D，E，J，T，p，q和x如本文所述的结构的化合物。在某些实施方案中，本文公开的化合物激活AMPK途径，并且可用于治疗与代谢有关的病症和病症。

4.

发明申请
PYRIMIDINEDIAMINE KINASE INHIBITORS 有权

公开(公告)号：US20130309228A1

公开(公告)日：2013-11-21

申请号：US13948342

申请日：2013-07-23

申请人： Rigel Pharmaceuticals, Inc.

发明人： Rajinder Singh , Andy Atuegbu , John Ramphal , Hui Li , Marina Gelman , Jeffrey Clough , Carlos Valdez , Somasekhar Bhamidipati , Sambaiah Thota , Darren McMurtrie

IPC分类号： A61K31/5383 , A61K45/06

CPC分类号： A61K31/5383 , A61K45/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/08 , C07D498/04

摘要： Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.

5.

发明申请
COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY 有权

公开(公告)号：US20130142807A1

公开(公告)日：2013-06-06

申请号：US13750632

申请日：2013-01-25

申请人： Rigel Pharmaceuticals, Inc.

发明人： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong

IPC分类号： A61K31/506 , A61K31/505 , C07F7/10 , A61K31/695 , C07D403/12 , C07D401/12 , A61K31/5377 , C07D413/12 , C07D413/14 , A61K31/541 , A61K31/538 , C07D498/04 , A61K31/5383 , A61K39/395 , A61K38/13 , A61K31/436 , A61K31/343 , C07D239/48

CPC分类号： C07D413/12 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/3955 , A61K45/06 , C07D239/42 , C07D239/48 , C07D285/22 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D413/14 , C07D417/12 , C07D498/04 , C07F7/0812 , C07F7/10

摘要： The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

6.

发明申请
COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY 有权

公开(公告)号：US20220098181A1

公开(公告)日：2022-03-31

申请号：US17517428

申请日：2021-11-02

申请人： Rigel Pharmaceuticals, Inc.

发明人： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong

IPC分类号： C07D413/12 , C07D403/04 , C07D239/42 , C07D401/12 , C07D403/12 , C07D413/14 , C07D239/48 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/395 , C07D498/04 , C07F7/10 , A61K45/06 , C07D401/14 , C07D417/12 , C07F7/08

摘要： The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

7.

发明授权
Compositions and methods for inhibition of the JAK pathway 有权

公开(公告)号：US11198689B2

公开(公告)日：2021-12-14

申请号：US16551393

申请日：2019-08-26

申请人： Rigel Pharmaceuticals, Inc.

发明人： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong

IPC分类号： C07D403/04 , C07D413/12 , C07D239/42 , C07D401/12 , C07D403/12 , C07D413/14 , C07D239/48 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/395 , C07D498/04 , C07F7/10 , A61K45/06 , C07D401/14 , C07D417/12 , C07F7/08 , C07D285/22

摘要： The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

8.

发明授权
Compositions and methods for inhibition of the JAK pathway 有权

公开(公告)号：US10421752B2

公开(公告)日：2019-09-24

申请号：US15637833

申请日：2017-06-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong

IPC分类号： A61K31/506 , C07D413/12 , C07D403/04 , C07D239/42 , C07D239/48 , C07D401/12 , C07D403/12 , C07D413/14 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/395 , C07D498/04 , C07F7/10 , A61K45/06 , C07D401/14 , C07D417/12 , C07F7/08 , C07D285/22

摘要： The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

9.

发明授权
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases 有权

公开(公告)号：US09624229B2

公开(公告)日：2017-04-18

申请号：US14243579

申请日：2014-04-02

申请人： Rigel Pharmaceuticals, Inc.

发明人： Somasekhar Bhamidipati , Jeffrey Clough , Ankush Argade , Rajinder Singh , Vadim Markovtsov , Pingyu Ding , Jiaxin Yu , Andy Atuegbu , Hui Hong , Ihab Darwish , Sambaiah Thota

IPC分类号： C07D487/08 , C07D451/00 , C07D451/04 , C07D491/08 , C07D519/00

CPC分类号： C07D487/08 , C07D451/00 , C07D451/04 , C07D491/08 , C07D519/00

摘要： This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, or a pharmaceutically acceptable salt.